Zacks Research Upgrades Pelthos Therapeutics (NYSEAMERICAN:PTHS) to “Hold”

Pelthos Therapeutics (NYSEAMERICAN:PTHS) was upgraded by equities researchers at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks reports.

Other equities research analysts also recently issued research reports about the company. Lake Street Capital cut their price target on Pelthos Therapeutics from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, October 12th. Oppenheimer reduced their price target on Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating on the stock in a research report on Friday, August 14th. Finally, Alliance Global Partners reiterated a “buy” rating on shares of Pelthos Therapeutics in a research note on Monday, October 26th. Seven analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $52.83.

Pelthos Therapeutics Price Performance

Pelthos Therapeutics stock opened at $9.30 on Wednesday. The company has a quick ratio of 1.31, a current ratio of 1.98 and a debt-to-equity ratio of 3.40. Pelthos Therapeutics has a 52-week low of $9.02 and a 52-week high of $37.50. The firm has a market cap of $35.62 million, a PE ratio of -0.43 and a beta of 3.41. The company’s 50 day moving average is $20.07 and its two-hundred day moving average is $23.91.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($6.62) EPS for the quarter. The business had revenue of $15.60 million during the quarter. Pelthos Therapeutics had a negative return on equity of 204.71% and a negative net margin of 165.24%. On average, research analysts expect that Pelthos Therapeutics will post -15.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Pelthos Therapeutics

A hedge fund recently raised its stake in Pelthos Therapeutics stock. Pale Fire Capital SE lifted its position in shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) by 59.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,919 shares of the company’s stock after purchasing an additional 4,819 shares during the period. Pale Fire Capital SE owned about 0.38% of Pelthos Therapeutics worth $271,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 77.96% of the company’s stock.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).